Directed share issue in XVIVO Perfusion AB (SE) — SEK 250 million

Carnegie acted as joint global co-ordinator and joint bookrunner in the directed share issue of 746,269 new shares at a subscription price of SEK 335 per share. Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. XVIVO’s solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
October 2021.